Ladies and gentlemen, greetings and welcome to the Longeveron Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the call over to Derek Cole of Investor Relations Advisory Solutions. Please go ahead.

Derek Cole

Thank you, Zico. Good afternoon, everyone, and thank you for joining us today to review Longeveron's third quarter 2024 financial results and business update. After the U.S. markets close today, we issued a press release with financial results for the third quarter, which can be found under the Investor section of the Longeveron website.

On the call with me today are Wa'el Hashad, Chief Executive Officer, Nataliya Agafonova, Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Joshua Hare, Co-Founder, Chief Science Officer and Chairman of the Board.

As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the questions from our analysts.

With that, let me hand the call over to Wa'el Hashad, Chief Executive